BioCentury | Oct 2, 2020
Product Development

With patient groups’ endorsement, Amylyx, FDA to discuss approval of ALS therapy

...Corp. (Tokyo:4508) in 2015, the agency proactively encouraged the pharma to submit the cerebral neuroprotectant and free radical...
BioCentury | Mar 20, 2020
Emerging Company Profile

Eikonizo: brain-penetrant HDAC inhibitors for neurodegeneration

Eikonizo aims to shore up axonal transport to treat neurodegenerative diseases, starting with ALS; and to de-risk its programs, the company is developing a companion PET tracer to confirm target engagement in vivo. The company's...
BioCentury | Oct 3, 2019
Targets & Mechanisms

ALS platform trial to put neuroinflammation hypothesis to the test

The largest test of the idea that ALS is driven by neuroinflammation will come from the first collaborative platform trial in the disease, which could blow open the range of pathways and targets in play...
BioCentury | May 29, 2019
Company News

CHMP against Emmaus' sickle cell therapy, Taiwan Liposome's doxorubicin

...MAA for Radicava edaravone to treat amyotrophic lateral sclerosis (ALS). The IV cerebral neuroprotectant and free radical...
BioCentury | Apr 18, 2019
Preclinical News

Pig brain tech could spur stroke therapies, drug and target validation

...of Hemopure, a hemoglobin-containing blood substitute from HbO2 Therapeutics LLC, spiked with sugars, antibiotics, a free radical...
BioCentury | Aug 3, 2018
Targets & Mechanisms

Oxitope’s oxidation play

...and molecular modeling experiments suggest the supplement may work in the wrong direction by promoting free radical...
BioCentury | Jan 5, 2018
Emerging Company Profile

Against radical pain

...pain types, such as inflammatory, neurogenic and neuropathic pain. Peroxynitrite is the most prevalent pain-induced free radical...
BioCentury | Nov 3, 2017
Regulation

Frame work

...amyotrophic lateral sclerosis (ALS) could decline with increasing disease severity. The IV cerebral neuroprotectant and free radical...
BioCentury | Sep 1, 2017
Company News

Mitsubishi launches ALS drug Radicava in U.S.

...14-day period, followed by a two-week drug-free period. Radicava is an IV cerebral neuroprotectant and free radical...
BioCentury | Jul 11, 2017
Emerging Company Profile

Complementary ALS play

...glutamate neurotransmitter levels. Mitsubishi Tanabe Pharma Corp. ’s Radicava is an IV cerebral neuroprotectant and free radical...
Items per page:
1 - 10 of 165
BioCentury | Oct 2, 2020
Product Development

With patient groups’ endorsement, Amylyx, FDA to discuss approval of ALS therapy

...Corp. (Tokyo:4508) in 2015, the agency proactively encouraged the pharma to submit the cerebral neuroprotectant and free radical...
BioCentury | Mar 20, 2020
Emerging Company Profile

Eikonizo: brain-penetrant HDAC inhibitors for neurodegeneration

Eikonizo aims to shore up axonal transport to treat neurodegenerative diseases, starting with ALS; and to de-risk its programs, the company is developing a companion PET tracer to confirm target engagement in vivo. The company's...
BioCentury | Oct 3, 2019
Targets & Mechanisms

ALS platform trial to put neuroinflammation hypothesis to the test

The largest test of the idea that ALS is driven by neuroinflammation will come from the first collaborative platform trial in the disease, which could blow open the range of pathways and targets in play...
BioCentury | May 29, 2019
Company News

CHMP against Emmaus' sickle cell therapy, Taiwan Liposome's doxorubicin

...MAA for Radicava edaravone to treat amyotrophic lateral sclerosis (ALS). The IV cerebral neuroprotectant and free radical...
BioCentury | Apr 18, 2019
Preclinical News

Pig brain tech could spur stroke therapies, drug and target validation

...of Hemopure, a hemoglobin-containing blood substitute from HbO2 Therapeutics LLC, spiked with sugars, antibiotics, a free radical...
BioCentury | Aug 3, 2018
Targets & Mechanisms

Oxitope’s oxidation play

...and molecular modeling experiments suggest the supplement may work in the wrong direction by promoting free radical...
BioCentury | Jan 5, 2018
Emerging Company Profile

Against radical pain

...pain types, such as inflammatory, neurogenic and neuropathic pain. Peroxynitrite is the most prevalent pain-induced free radical...
BioCentury | Nov 3, 2017
Regulation

Frame work

...amyotrophic lateral sclerosis (ALS) could decline with increasing disease severity. The IV cerebral neuroprotectant and free radical...
BioCentury | Sep 1, 2017
Company News

Mitsubishi launches ALS drug Radicava in U.S.

...14-day period, followed by a two-week drug-free period. Radicava is an IV cerebral neuroprotectant and free radical...
BioCentury | Jul 11, 2017
Emerging Company Profile

Complementary ALS play

...glutamate neurotransmitter levels. Mitsubishi Tanabe Pharma Corp. ’s Radicava is an IV cerebral neuroprotectant and free radical...
Items per page:
1 - 10 of 165